cositecan has been researched along with Melanoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM | 1 |
| Daud, AI; Munster, PN | 1 |
| Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
1 review(s) available for cositecan and Melanoma
| Article | Year |
|---|---|
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Topics: Animals; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2011 |
2 trial(s) available for cositecan and Melanoma
| Article | Year |
|---|---|
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Melanoma; Mice; Mice, Nude; Middle Aged; Skin Neoplasms; Topoisomerase I Inhibitors; Valproic Acid | 2009 |
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2005 |
1 other study(ies) available for cositecan and Melanoma
| Article | Year |
|---|---|
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |